Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 20/20 | 0.67 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 1/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.59 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17607134 | 0.92 | MAPK7 (0.66) | MAPK7AURKADCLK1ABL1CSF1R | |
| SCHEMBL20265760 | 0.83 | MAPK7 (0.64) | MAPK7AURKADCLK1ABL1CSF1R | |
| SCHEMBL20265707 | 0.83 | MAPK7 (0.66) | MAPK7AURKADCLK1ABL1CSF1R | |
| SCHEMBL17607135 | 0.83 | MAPK7 (0.65) | MAPK7AURKADCLK1ABL1CSF1R | |
| SCHEMBL17607106 | 0.82 | MAPK7 (0.73) | MAPK7AURKADCLK1ABL1CSF1R | |
| SCHEMBL17607092 | 0.81 | MAPK7 (0.76) | MAPK7AURKADCLK1ABL1CSF1R | |
| SCHEMBL17607148 | 0.81 | MAPK7 (0.77) | MAPK7AURKADCLK1ABL1CSF1R | |
| SCHEMBL20265752 | 0.80 | MAPK7 (0.80) | MAPK7AURKADCLK1ABL1CSF1R | |
| SCHEMBL17607124 | 0.80 | MAPK7 (0.70) | MAPK7AURKADCLK1ABL1CSF1R | |
| SCHEMBL20265901 | 0.80 | MAPK7 (1.00) | MAPK7AURKADCLK1ABL1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344017-B2 | Pyrrolcarboxamide derivatives for the inhibition of ERK5 | CANCER RESEARCH TECH LTD (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180170911-A1 | PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170911-A1 | PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5 | MAPKAPK5, MAP3K5, MAPK15 | MAPK7 38/4885AURKA 2742/4885DCLK1 2762/4885 |
| US-10344017-B2 | Pyrrolcarboxamide derivatives for the inhibition of ERK5 | MAPKAPK5, MAP3K5, MAPK15 | MAPK7 38/4885AURKA 2742/4885DCLK1 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.